#United States #New York #Securities Fraud #Pomerantz LLP #Fulgent Genetics

Pomerantz Law Firm Launches Investigation Regarding Claims from Fulgent Genetics Investors

In a recent announcement, Pomerantz LLP, a law firm recognized for its leadership in securities litigation, has initiated an investigation into the claims submitted by investors of Fulgent Genetics, Inc. (NASDAQ: FLGT). The firm aims to determine whether the company, along with its officers and directors, has engaged in securities fraud or any other unlawful business conducts that may have adversely affected its investors.

Background on Fulgent Genetics' Financial Performance

On February 27, 2026, Fulgent Genetics released its financial results for the fourth quarter of 2025 as well as its full-year performance. The announcement included disappointing projections for 2026, which suggested a significant decline to its revenue expectations. According to Fulgent's report, the drop was primarily due to a key customer deciding to handle a substantial portion of its operations internally, thereby reducing its dependence on Fulgent's services.

Following this announcement, Fulgent's stock price suffered a sharp decline, plummeting by $9.43—an alarming 38.09% drop—to close at $15.33 per share. Such a significant price fluctuation has alarmed many investors, triggering concerns about the integrity of the company's financial statements and its administrative practices in general.

The Role of Pomerantz LLP

Pomerantz LLP has gained a reputation for being at the forefront of the legal battle against corporate wrongdoing, especially in the realm of securities fraud. With offices located in major cities across the globe including New York, Chicago, and Los Angeles, the firm has a storied history of advocating for investors' rights. Founded by Abraham L. Pomerantz, often referred to as the "dean of the class action bar," the firm has successfully recovered vast monetary damages for victims of securities fraud and breaches of fiduciary duty.

The firm invites investors affected by Fulgent's recent stock performance to reach out for more information regarding class-action claims. Those interested can contact attorney Danielle Peyton directly via email or phone, as detailed in their public statement.

What Investors Should Consider

Investors who have suffered financial losses due to the latest developments concerning Fulgent Genetics should be proactive in assessing their situation. Engaging with a law firm that specializes in securities litigation can provide guidance on potential legal recourse. The investigation by Pomerantz LLP reflects a broader concern over the transparency of not only Fulgent’s operations but also the financial integrity prevalent in the biotech industry.

Pomerantz’s investigation will focus on parsing through the recent disclosures made by Fulgent as well as examining communications made about future financial expectations. The findings could be pivotal in determining whether the company acted lawfully or if significant misrepresentations were made to investors.

In conclusion, while Fulgent Genetics grapples with declining stock and investor concerns, Pomerantz LLP is prepared to fight for those whose investments may have been undermined by questionable business practices. Interested parties should stay informed as the situation unfolds, and they should not hesitate to leverage their legal rights in the face of potential wrongdoing. For continued updates, the firm’s website and communication channels will likely provide further information regarding the progress of the investigation and any subsequent actions that may arise.